Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Trial

Marius Trøseid, Alpha Diallo, Lambert Assoumou et al.|SSRN Electronic Journal|2022

Cited by 1